Table 3.
Multivariate analysis of ORR and OS with XBP1 and CD44 expression in 62 patients with PCNS-DLBCL
| Variable | No | XBP1 (%) | CD44 (%) | ORR (%) | 3-year OS (%) | χ | P value |
|---|---|---|---|---|---|---|---|
| APVI | |||||||
| Positive | 54 | 46 (87) | 42 (78) | 18 (34) | 31 ± 9 | ||
| Negative | 8 | 2 (33) | 2 (33) | 6 (83) | 64 ± 6 | 18.8162 | .0021 |
| RPVI | |||||||
| Positive | 20 | 1 (8) | 5 (25) | 15 (75) | 37 ± 9 | ||
| Negative | 42 | 30 (73) | 35 (84) | 19 (46) | 32 ± 7 | 29.5332 | .0001 |
| IELSG prognosis score | |||||||
| Low | 13 | 4 (37) | 3 (25) | 11 (88) | 69 ± 8 | ||
| Intermediate | 23 | 17 (75) | 18 (81) | 17 (75) | 41 ± 7 | ||
| High | 26 | 20 (79) | 22 (86) | 7 (29) | 6 ± 9 | 24.872 | .0056 |
| Treatment | |||||||
| Radiotherapy | 31 | 16 (52) | 26 (84) | 8 (26) | 24 ± 9 | ||
| Chemotherapy | 57 | 45 (80) | 46 (82) | 16 (29) | 43 ± 6 | 0.4714 | .4837 |
| High-dose Methotrexate | |||||||
| Yes | 38 | 26 (70) | 28 (76) | 28 (76) | 60 ± 7 | ||
| No | 24 | 17 (71) | 19 (81) | 12 (52) | 22 ± 8 | 2.4598 | .7825 |
Abbreviations: APVT, aggregative perivascular tumor cell; IELSG, International Extranodal Lymphoma Study Group; RPVI, reactive perivascular T cell infiltrate.